Clinical Trial Update: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a phase 1/2 study evaluating the CVDD combination (cyclophosphamide, bortezomib, liposomal doxorubicin, and dexamethasone) in n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Doxil (liposomal doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-01-20